Table 1:
Baseline patient characteristics and age-adjusted hazard ratios (HR) for tumor characteristics in relation to disease-free survival (CHCAMS) and overall survival (PBCS and PLCO)
| Study population | ||||||
|---|---|---|---|---|---|---|
| CHCAMS (n = 596) | PBCS (n = 810) | PLCO (n = 678) | ||||
| Freq (%) | HR (95% CI) | Freq (%) | HR (95% CI) | Freq (%) | HR (95% CI) | |
| Age, years | ||||||
| <35 | 60 (10.1) | 6 (0.7) | NA | |||
| 35-50 | 467 (78.3) | 215 (26.5) | NA | |||
| 50-65 | 69 (11.6) | 378 (46.7) | 227 (33.5) | |||
| >65 | NA | 211 (26.1) | 451 (66.5) | |||
| Median age (range) | 44 (24-55) | 55 (31-75) | 67 (55-87) | |||
| Median FU (range), years | 7 (0.2-11.2) | 15 (0.2-18.5) | 11 (0.1-21) | |||
| Events (DFS/OS) | ||||||
| Absent | 475 (81.9) | 443 (55.4) | 486 (71.7) | |||
| Present | 105 (18.1) | 356 (44.6) | 192 (28.3) | |||
| Endocrine | NA | |||||
| No | 97 (16.3) | 464 (57.3) | ||||
| Yes | 499 (83.7) | 346 (42.7) | ||||
| Trastuzumab | NA | |||||
| No | 567 (95.1) | 798 (98.5) | ||||
| Yes | 29 (4.9) | 12 (1.5) | ||||
| ER status | ||||||
| Negative | 0 () | 249 (31.4) | 1.00 (reference) | 153 (24.2) | 1.00 (reference) | |
| Positive | 596 (100) | 544 (68.6) | 0.60 (0.46, 0.78) | 480 (75.8) | 0.70 (0.48, 1.00) | |
| PR status | ||||||
| Negative | 31 (5.2) | 1.00 (reference) | 373 (47.1) | 1.00 (reference) | 273 (46.1) | 1.00 (reference) |
| Positive | 565 (94.8) | 0.70 (0.32, 1.50) | 419 (52.9) | 0.53 (0.41, 0.69) | 319 (53.9) | 0.76 (0.53, 1.09) |
| HER2 | ||||||
| Negative | 415 (77.4) | 1.00 (reference) | 590 (83.3) | 1.00 (reference) | 365 (84.5) | 1.00 (reference) |
| Positive | 121 (22.6) | 0.62 (0.36, 1.07) | 118 (16.7) | 1.73 (1.25, 2.39) | 67 (15.5) | 1.71 (1.08, 2.73) |
| Subtype | ||||||
| Lum A-like | 326 (60.a8) | 1.00 (reference) | 282 (40.0) | 1.00 (reference) | 129 (35.7) | 1.00 (reference) |
| Lum B-like | 210 (39.2) | 0.94 (0.62, 1.42) | 256 (36.3) | 1.55 (1.11, 2.18) | 132 (36.6) | 1.28 (0.74, 2.19) |
| HER2-enriched | NA | NA | 54 (7.6) | 2.79 (1.73, 4.49) | 28 (7.7) | 2.12 (0.98, 4.58) |
| TNBC | NA | NA | 114 (16.1) | 2.33 (1.56, 3.49) | 72 (20.0) | 1.86 (1.03, 3.37) |
| IHC4 score | NA | |||||
| Median | 48.9 | 67.5 | ||||
| Q1 | 107 (25.2) | 1.00 (reference) | 117 (25.0) | 1.00 (reference) | ||
| Q2 | 105 (24.7) | 2.08 (0.98, 4.43) | 117 (25.0) | 1.12 (0.66, 1.92) | ||
| Q3 | 105 (24.7) | 1.14 (0.51, 2.58) | 117 (25.0) | 1.49 (0.89, 2.49) | ||
| Q4 | 108 (25.4) | 1.82 (0.86, 3.84) | 117 (25.0) | 1.37 (0.81, 2.31) | ||
| Grade | ||||||
| Low | 71 (11.9) | 1.00 (reference) | 141 (17.4) | 1.00 (reference) | 158 (24.8) | 1.00 (reference) |
| Intermediate | 385 (64.6) | 1.42 (0.71, 2.86) | 455 (56.2) | 1.07 (0.73, 1.57) | 278 (43.6) | 1.64 (1.02, 2.62) |
| High | 140 (23.5) | 1.66 (0.79, 3.51) | 214 (26.4) | 1.93 (1.30, 2.87) | 201 (31.6) | 2.16 (1.33, 3.50) |
| Size (cm) | ||||||
| ≤2 | 220 (67.7) | 1.00 (reference) | 398 (51.8) | 1.00 (reference) | 475 (70.5) | 1.00 (reference) |
| >2 | 105 (32.3) | 1.62 (0.98, 2.66) | 371 (48.2) | 2.25 (1.71, 2.96) | 199 (29.5) | 2.08 (1.50, 2.88) |
| Node status | ||||||
| Negative | 351 (58.9) | 1.00 (reference) | 448 (59.0) | 1.00 (reference) | 463 (71.7) | 1.00 (reference) |
| Positive | 245 (41.1) | 2.52 (1.71, 3.73) | 311 (41.0) | 2.10 (1.61, 2.73) | 183 (28.3) | 2.07 (1.47, 2.90) |
| Stage | ||||||
| I | 265 (44.5) | 1.00 (reference) | 135 (25.8) | 1.00 (reference) | 383 (56.8) | 1.00 (reference) |
| II | 252 (42.3) | 1.69 (1.08, 2.66) | 375 (71.7) | 2.47 (1.52, 4.00) | 256 (38.0) | 1.75 (1.24, 2.46) |
| III/IV | 79 (13.3) | 3.26 (1.94, 5.48) | 13 (2.5) | 1.10 (0.26, 4.70) | 35 (5.2) | 4.62 (2.72, 7.84) |
CHCAMS: Cancer Hospital, Chinese Academy of Medical Sciences; PBCS: Polish Breast Cancer Study; PLCO: Prostate, Lung, Colorectal and Ovarian cancer screening trial in the United States. Breast cancer patients from CHCAMS were premenopausal women, aged 24-55 years, with hormone receptor-positive (HR+) breast cancer that were diagnosed between 2008-2012. Patients from PBCS were women aged 31-75 years, unselected for hormone receptor-status, diagnosed between 2000-2003. PLCO patients were postmenopausal women, aged 55-87 years, unselected for hormone receptor-status, that were participating in the PLCO trial (1993-2001). NA: Not available or applicable. FU: follow-up. HR: Hazard ratio; 95% CI: 95% Confidence interval. DFS: Disease-free survival. OS: Overall survival. ER: estrogen receptor. PR: progesterone receptor. HER2: human epiderma growth factor receptor 2.